| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 83431 |
NHS ester-PEG4-VC-PAB-Daunorubicin，ADC定制 |
155 |
wyh |
2024-12-19 |
| 83432 |
Mal-PEG3-Val-Cit-PAB-OH（CAS: 2727965-49-1） |
154 |
WYQ |
2024-12-19 |
| 83433 |
cas:1539292-60-8，tert-butyl 3-(4-(2-cyanoethynyl)phenylcarbamoyl)propylcarbamate |
109 |
zyl |
2024-12-19 |
| 83434 |
1281816-04-3，Lys-Nε-MCC-DM1，ADC定制 |
107 |
wyh |
2024-12-19 |
| 83435 |
cas:34450-18-5，Alkynyl Stearic Acid，17-十八炔酸 |
183 |
zyl |
2024-12-19 |
| 83436 |
Mal-PEG4-Val-Cit-PAB-OH（CAS: 2055041-39-7） |
155 |
WYQ |
2024-12-19 |
| 83437 |
1281816-04-3，Lys-Nε-MCC-DM1，ADC定制 |
117 |
wyh |
2024-12-19 |
| 83438 |
cas:120550-35-8，Biotin-PFP ester，五氟苯酚生物素酯 |
306 |
zyl |
2024-12-19 |
| 83439 |
MTS-ADO3A 三酸DOTA衍生物 |
165 |
h |
2024-12-19 |
| 83440 |
NHS-PEG2-NH-Xanomeline，ADC定制 |
132 |
wyh |
2024-12-19 |
| 83441 |
DOTA-DAsp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH2 DOTA-CCK |
181 |
h |
2024-12-19 |
| 83442 |
DOTA-MN2 2,2’-[4,10-双(2-{[2-(2-甲基-5-硝基-1H-咪唑-1-基)乙基]氨基}-2-氧乙基)-1,4,7,10-四氮杂环十二烷-1,7-二基]二乙酸 |
128 |
h |
2024-12-19 |
| 83443 |
cas:2123482-78-8，TETRAZINE-SS-BIOTIN 四嗪-双硫键-生物素 |
123 |
zyl |
2024-12-19 |
| 83444 |
GG-Tesirine，ADC定制 |
189 |
wyh |
2024-12-19 |
| 83445 |
DOTA-PEG-A20FMDV2 DOTA偶联聚乙二醇化的20个残基的线性肽 |
207 |
h |
2024-12-19 |
| 83446 |
MC-GGFG-Exatecan，ADC定制 |
217 |
wyh |
2024-12-19 |
| 83447 |
亲和素-AMF-DOTA(Nd) |
160 |
h |
2024-12-19 |
| 83448 |
DOTA偶联人血清白蛋白微球 DOTA-HSAM |
282 |
h |
2024-12-19 |
| 83449 |
MC-VA-PBD，MC-Val-Ala-PBD，ADC定制 |
324 |
wyh |
2024-12-19 |
| 83450 |
cas:2241685-22-1，DADPS Biotin Alykne |
143 |
zyl |
2024-12-19 |
| 83451 |
MC-vc-PAB-C6-Alpha-Amanitin，ADC定制 |
142 |
wyh |
2024-12-19 |
| 83452 |
MPB-MMAF，ADC定制 |
203 |
wyh |
2024-12-19 |
| 83453 |
DOTA–Bipy–RuII配位共轭物 |
286 |
h |
2024-12-19 |
| 83454 |
cas:1007215-91-9，1-(4-formylphenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-13-oic acid |
168 |
zyl |
2024-12-19 |
| 83455 |
DOTA-cT84.66 DOTA偶联单克隆抗体cT84.66 |
139 |
h |
2024-12-19 |
| 83456 |
DOTA-Ahx-(D-Lys(6)-GnRH1)金属螯合剂DOTA偶联氨基己酸缀合D-赖氨酸 |
151 |
h |
2024-12-19 |
| 83457 |
DOTA-LRB 2-(6-(二乙基氨基)-3-(二乙基亚胺基)-3H-呫吨-9-基)-5-(N-(2-(2-(4,7,10-三(羧甲基)-1,4,7,10-四氮杂环十二烷-1-基)乙酰胺基 |
160 |
h |
2024-12-19 |
| 83458 |
DOTA-Y3-TATE DOTA偶联激动剂Y3-TATE |
170 |
h |
2024-12-19 |
| 83459 |
DOTA-2-脱氧-D-氨基葡萄糖 DOTA-DG |
182 |
h |
2024-12-19 |
| 83460 |
DOTA-c(RGDfK)DOTA偶联环肽 |
123 |
h |
2024-12-19 |
| 83461 |
SCN-DOTA-PCA DOTA-苯甲酰胺衍生物 |
168 |
h |
2024-12-19 |
| 83462 |
DOTA-N-羟基琥珀酰亚胺 DOTA-N-hydroxysuccinimide |
149 |
h |
2024-12-19 |
| 83463 |
低分子量CLT1肽靶向Gd(III)螯合物CLT1-dL-(Gd-DOTA) |
235 |
h |
2024-12-19 |
| 83464 |
DOTA-1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺脂质 |
208 |
h |
2024-12-19 |
| 83465 |
1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA17,19) |
155 |
h |
2024-12-19 |
| 83466 |
cas:1061569-06-9，4-formyl-N-(2-(2-hydroxyethoxy)ethyl)benzamide ADC抗体偶联药物 |
122 |
zyl |
2024-12-19 |
| 83467 |
DBCO-PEG4-VA-PBD，2241644-09-5，ADC定制 |
108 |
wyh |
2024-12-19 |
| 83468 |
Val-Cit-PAB-MMAE，cas:644981-35-1，ADC定制 |
139 |
wyh |
2024-12-19 |
| 83469 |
DOTA-GMSH 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)偶联α-黑素细胞刺激素(α-MSH)类似物 |
179 |
h |
2024-12-19 |
| 83470 |
mDPR-Val-Cit-PAB-MMAE，1491152-26-1，ADC定制 |
123 |
wyh |
2024-12-19 |
| 83471 |
G3-(Gd-DTPA)(24)DOTA-钆(Gd)大分子造影剂 |
322 |
h |
2024-12-19 |
| 83472 |
DOTA-多柔比星 DOTA-DOX |
164 |
h |
2024-12-19 |
| 83473 |
聚(HPMA)-c(RGDyK)-DOTA |
110 |
h |
2024-12-19 |
| 83474 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)螯合剂共轭的应变环辛烯衍生物二苄基环辛烯(DBCO) |
144 |
h |
2024-12-19 |
| 83475 |
PDDEC-NB；2-methyl-2-(pyridin-2-yldisulfanyl)propyl 4-nitrophenyl carbonate |
107 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询